Real-world study of donor stem cell transplant for relapsed/refractory myeloma

This trial tests a new way of doing a stem cell transplant using cells from a donor to treat multiple myeloma that has come back or not responded to standard treatments. It also aims to prevent the cancer from coming back by using special cells that are not removed from the donor's stem cells.

This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.

This study is a registry that tracks outcomes for adults with blood diseases (such as leukemia, lymphoma, or severe aplastic anemia) who receive a haploidentical stem cell transplant—a transplant from a half-matched donor. The goal is to gather real-world data to understand how well this approach works for people who do not have a fully matched donor.

This study looks at outcomes of an allogeneic transplant (a donor-based transplant) in people with stage II–III multiple myeloma or primary plasma cell leukemia who have Medicare. It may help doctors better understand which patients benefit and what to expect before and after transplant.

This study follows people with multiple myeloma that has come back or stopped responding to treatment, and looks at how current care is used in real life. It may include people starting talquetamab, and aims to understand outcomes and treatment patterns outside of strict experimental settings.

This study looks at why a bone marrow disorder (MDS) can come back after a donor stem cell transplant. It may help researchers understand relapse, which could improve future care for people getting transplants.